semaglutide bmi 25 Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Finally just overweight instead of

Treatment can: Support significant, sustained weight reduction Lower the risk of heart disease, stroke, and some cancers Improve mobility and make physical activity easier Reduce high blood pressure Improve sleep quality Help manage type 2 diabetes when present Reduce the need for invasive procedures like bariatric surgery Improve blood sugar control and metabolic health Provide both injection and tablet options for flexibility Allow for daily or weekly dosing depending on the program Be used safely for long-term weight management Risks & Side Effects Serious complications from semaglutide are rare, but side effects are possible

This slowing down can lead to feelings of fullness, nausea, and indigestion, which are already common in patients with gastritis

Our consultations and follow-up visits are designed to ensure your program is safe, effective, and tailored to your body

Unraveling cellular pathways contributing to drug-induced liver injury by dynamical modeling

Funding This work is supported by Eli Lilly and Company